Authors:
FISHER RC
OLSON MC
PONGUBALA JMR
PERKEL JM
ATCHISON ML
SCOTT EW
SIMON MC
Citation: Rc. Fisher et al., NORMAL MYELOID DEVELOPMENT REQUIRES BOTH THE GLUTAMINE-RICH TRANSACTIVATION DOMAIN AND THE PEST REGION OF TRANSCRIPTION FACTOR PU.1 BUT NOTTHE POTENT ACIDIC TRANSACTIVATION DOMAIN, Molecular and cellular biology, 18(7), 1998, pp. 4347-4357
Authors:
SCOTT EW
FISHER RC
OLSON MC
KEHRLI EW
SIMON MC
SINGH H
Citation: Ew. Scott et al., PU.1 FUNCTIONS IN A CELL-AUTONOMOUS MANNER TO CONTROL THE DIFFERENTIATION OF MULTIPOTENTIAL LYMPHOID-MYELOID PROGENITORS, Immunity, 6(4), 1997, pp. 437-447
Authors:
FISHER RC
OLSON MC
PONGUBALA JMR
ATCHISON ML
SIMON MC
SCOTT EW
Citation: Rc. Fisher et al., NORMAL MYELOID DEVELOPMENT REQUIRES BOTH THE GLUTAMINE-RICH DOMAIN AND THE PEST DOMAIN OF THE TRANSACTIVATION FATTER PU.1 - ACIDIC ACTIVATION DOMAINS, POTENT TRANSACTIVATORS IN-VITRO, HAVE NO ROLE, Blood, 90(10), 1997, pp. 1783-1783
Citation: Rc. Fisher et Ew. Scott, THE TRANSCRIPTION FACTOR PU.1 REGULATES DIFFERENTIATION OF MULTIPOTENTIAL LYMPHOID-MYELOID PROGENITORS IN A CELL AUTONOMOUS MANNER, Experimental hematology, 24(9), 1996, pp. 91-91
Authors:
OLSON MC
SCOTT EW
HACK AA
SU GH
TENEN DG
SINGH H
SIMON MC
Citation: Mc. Olson et al., PU.1 IS NOT ESSENTIAL FOR EARLY MYELOID GENE-EXPRESSION BUT IS REQUIRED FOR TERMINAL MYELOID DIFFERENTIATION, Immunity, 3(6), 1995, pp. 703-714
Authors:
NATARAJAN V
PLISHKA RJ
SCOTT EW
LANE HC
SALZMAN NP
Citation: V. Natarajan et al., AN INTERNALLY CONTROLLED VIRION PCR FOR THE MEASUREMENT OF HIV-1 RNA IN PLASMA, PCR methods and applications, 3(6), 1994, pp. 346-350
Citation: Ew. Scott et H. Singh, GENETIC-ANALYSIS OF OCT-2 AND PU.1 FUNCTION DURING B-CELL DEVELOPMENT, Journal of cellular biochemistry, 1994, pp. 378-378
Citation: Ew. Scott et al., REQUIREMENT OF TRANSCRIPTION FACTOR PU.1 IN THE DEVELOPMENT OF MULTIPLE HEMATOPOIETIC LINEAGES, Science, 265(5178), 1994, pp. 1573-1577
Citation: Ha. Benchaoui et al., PHARMACOKINETICS OF ALBENDAZOLE, ALBENDAZOLE SULFOXIDE AND NETOBIMIN IN GOATS, Journal of veterinary pharmacology and therapeutics, 16(2), 1993, pp. 237-240